CoChat
Sign Up
Cited by 84

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The tuberous sclerosis complex proteins – a GRIPP on cognition and neurodevelopment

de Vries, Petrus J., Howe, Christopher J.·2007·Trends in Molecular Medicine
DOI 10.1016/j.molmed.2007.06.003
Open this paper in CoChat — free account

Abstract

Tuberous sclerosis complex (TSC) is a multi-system disorder associated with mutations in the TSC1 (hamartin) or TSC2 (tuberin) genes. The neurocognitive features of TSC show wide variability and have generally been attributed to structural brain abnormalities and/or seizures. We review the fundamental roles of TSC1 and TSC2 in cell signalling and propose that because the hamartin-tuberin complex (hereafter referred to as TSC1-2) acts as a global regulator and integrator of a range of physiological processes ('GRIPP') the neurocognitive manifestations of TSC result directly from cell-signalling abnormalities. Under the GRIPP hypothesis, the spectrum of neurodevelopmental abnormalities is caused by the biochemical consequences of individual TSC1 and TSC2 mutations. Recognizing the importance of signalling disruption in the brain might improve our understanding of other neurocognitive disorders.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.molmed.2007.06.003

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 67

  1. Povey, 1994, Two loci for tuberous sclerosis: one on 9q34 and one on 16p13, Ann. Hum. Genet., 58, 107, 10.1111/j.1469-1809.1994.tb01881.x · DOI
  2. Naarding, 2001, Huntington's Disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena, Eur. Psychiatry, 16, 439, 10.1016/S0924-9338(01)00604-6 · DOI
  3. Morris, 1988, Natural history of Williams syndrome: physical characteristics, J. Pediatr., 113, 318, 10.1016/S0022-3476(88)80272-5 · DOI
  4. 1993, Identification and characterisation of the tuberous sclerosis gene on chromosome 16, Cell, 75, 1305, 10.1016/0092-8674(93)90618-Z · DOI · Paper page
  5. Van Slegtenhorst, 1997, Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34, Science, 277, 805, 10.1126/science.277.5327.805 · DOI · Paper page
  6. Roach, 1998, Tuberous Sclerosis Consensus Conference: Revised Diagnostic Criteria, J. Child Neurol., 13, 624, 10.1177/088307389801301206 · DOI
  7. Franz, 2001, Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis, Am. J. Respir. Crit. Care Med., 164, 661, 10.1164/ajrccm.164.4.2011025 · DOI
  8. Jones, 1997, Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis, Hum. Mol. Genet., 6, 2155, 10.1093/hmg/6.12.2155 · DOI
  9. Dabora, 2001, Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs, Am. J. Hum. Genet., 68, 64, 10.1086/316951 · DOI
  10. Lewis, 2004, Genotype and psychological phenotype in tuberous sclerosis, J. Med. Genet., 41, 203, 10.1136/jmg.2003.012757 · DOI
  11. Doherty, 2005, Prognostic significance of tuber count and location in tuberous sclerosis complex, J. Child Neurol., 20, 837, 10.1177/08830738050200101301 · DOI
  12. Au, 2007, Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States, Genet. Med., 9, 88, 10.1097/GIM.0b013e31803068c7 · DOI
  13. Sancak, 2005, Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex, Eur. J. Hum. Genet., 13, 731, 10.1038/sj.ejhg.5201402 · DOI
  14. Van Slegtenhorst, 1998, Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products, Hum. Mol. Genet., 7, 1053, 10.1093/hmg/7.6.1053 · DOI · Paper page
  15. Kwiatkowski, 2005, Tuberous Sclerosis: a GAP at the crossroads of multiple signalling pathways, Hum. Mol. Genet., 14, R251, 10.1093/hmg/ddi260 · DOI · Paper page
  16. Inoki, 2005, Dysregulation of the TSC-mTOR pathway in human disease, Nat. Genet., 37, 19, 10.1038/ng1494 · DOI
  17. Tee, 2005, mTOR, translational control and human disease, Semin. Cell Dev. Biol., 16, 29, 10.1016/j.semcdb.2004.11.005 · DOI
  18. Mak, 2005, Aberrant β-Catenin Signaling in Tuberous Sclerosis, Am. J. Pathol., 167, 107, 10.1016/S0002-9440(10)62958-6 · DOI
  19. Astrinidis, 2003, Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B, J. Biol. Chem., 278, 51372, 10.1074/jbc.M303956200 · DOI
  20. Ma, 2005, Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis, Cell, 121, 179, 10.1016/j.cell.2005.02.031 · DOI · Paper page
  21. Roux, 2004, Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase, Proc. Natl. Acad. Sci. U. S. A., 101, 13489, 10.1073/pnas.0405659101 · DOI
  22. Ballif, 2005, Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors, Proc. Natl. Acad. Sci. U. S. A., 102, 667, 10.1073/pnas.0409143102 · DOI
  23. Li, 2003, The p38 and MK2 Kinase Cascade Phosphorylates Tuberin, the Tuberous Sclerosis 2 Gene Product, and Enhances Its Interaction with 14-3-3, J. Biol. Chem., 278, 13663, 10.1074/jbc.M300862200 · DOI
  24. Dan, 2002, Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin, J. Biol. Chem., 277, 35364, 10.1074/jbc.M205838200 · DOI
  25. Manning, 2002, Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway, Mol. Cell, 10, 151, 10.1016/S1097-2765(02)00568-3 · DOI · Paper page
  26. Inoki, 2003, TSC2 mediates cellular energy response to control cell growth and survival, Cell, 115, 577, 10.1016/S0092-8674(03)00929-2 · DOI · Paper page
  27. Inoki, 2006, TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth, Cell, 126, 955, 10.1016/j.cell.2006.06.055 · DOI · Paper page
  28. Lamb, 2000, The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho, Nat. Cell Biol., 2, 281, 10.1038/35010550 · DOI
  29. Noonan, 2002, A calmodulin binding site in the tuberous sclerosis 2 gene is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis, Arch. Biochem. Biophys., 398, 132, 10.1006/abbi.2001.2682 · DOI
  30. York, 2005, Cross-talk between tuberin, calmodulin, and estrogen signalling pathways, FASEB J., 19, 1202, 10.1096/fj.04-3142fje · DOI
  31. Rosner, 2007, Akt regulates nuclear/cytoplasmic localization of tuberin, Oncogene, 26, 521, 10.1038/sj.onc.1209812 · DOI
  32. Matsumoto, 2002, Role of the Tsc1-Tsc2 complex in signalling and transport across the cell membrane in the fission yeast Schizosaccharomyces pombe, Genetics, 161, 1053, 10.1093/genetics/161.3.1053 · DOI
  33. Goncharova, 2004, TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase, J. Cell Biol., 167, 1171, 10.1083/jcb.200405130 · DOI
  34. Herry, 2007, Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex, Eur. J. Intern. Med., 18, 76, 10.1016/j.ejim.2006.07.017 · DOI
  35. Franz, 2006, Rapamycin causes regression of astrocytomas in tuberous sclerosis complex, Ann. Neurol., 59, 490, 10.1002/ana.20784 · DOI
  36. Chan, 2004, Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation, J. Neuropathol. Exp. Neurol., 63, 1236, 10.1093/jnen/63.12.1236 · DOI
  37. Henske, 1996, Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions, Am. J. Hum. Genet., 59, 400
  38. Prather, 2004, Behavioral and cognitive aspects of tuberous sclerosis complex, J. Child Neurol., 19, 666, 10.1177/08830738040190090601 · DOI
  39. de Vries, 2007, The tuberous sclerosis complex, N. Engl. J. Med., 356, 92, 10.1056/NEJMc062928 · DOI · Paper page
  40. Joinson, 2003, Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex, Psychol. Med., 33, 335, 10.1017/S0033291702007092 · DOI · Paper page
  41. Ridler, 2007, Neuroanatomical correlates of memory deficits in tuberous sclerosis complex, Cereb. Cortex, 17, 261, 10.1093/cercor/bhj144 · DOI · Paper page
  42. Goodman, 1997, Cortical tuber count: a biomarker indicating neurological severity of tuberous sclerosis complex, J. Child Neurol., 12, 85, 10.1177/088307389701200203 · DOI
  43. O’Callaghan, 2004, The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex, Arch. Dis. Child., 89, 530, 10.1136/adc.2003.026815 · DOI
  44. Raznahan, 2007, Biological markers of intellectual disability in tuberous sclerosis, Psychol. Med., 10.1017/S0033291707000177 · DOI
  45. Wong, 2006, Tuberous sclerosis complex: correlation of magnetic resonance imaging (MRI) findings with comorbidities, J. Child Neurol., 21, 99, 10.1177/08830738060210020901 · DOI
  46. Hentges, 2001, FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse, Proc. Natl. Acad. Sci. U. S. A., 98, 13796, 10.1073/pnas.241184198 · DOI
  47. Ridler, 2001, Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis, Psychol. Med., 31, 1437, 10.1017/S0033291701004561 · DOI
  48. Andreasson, 2002, Role of immediate early gene expression in cortical morphogenesis and plasticity, Results Probl. Cell Differ., 39, 113, 10.1007/978-3-540-46006-0_6 · DOI
  49. Lanahan, 1998, Immediate-Early Genes and Synaptic Function, Neurobiol. Learn. Mem., 70, 37, 10.1006/nlme.1998.3836 · DOI
  50. Ogata, 2004, Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination, J. Neurosci., 24, 6724, 10.1523/JNEUROSCI.5520-03.2004 · DOI
  51. Newey, 2005, Rho GTPases, dendritic structure, and mental retardation, J. Neurobiol., 64, 58, 10.1002/neu.20153 · DOI · Paper page
  52. Chen, 2005, PI3 kinase signalling is required for retrieval and extinction of contextual memory, Nat. Neurosci., 8, 925, 10.1038/nn1482 · DOI
  53. Thomas, 2004, MAPK cascade signalling and synaptic plasticity, Nat. Rev. Neurosci., 5, 173, 10.1038/nrn1346 · DOI · Paper page
  54. Von der Brelie, 2006, Impaired synaptic plasticity in a rat model of tuberous sclerosis, Eur. J. Neurosci., 23, 686, 10.1111/j.1460-9568.2006.04594.x · DOI · Paper page
  55. Ramamurthy, 2006, Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain, J. Physiol., 574, 85, 10.1113/jphysiol.2006.110122 · DOI
  56. Shaw, 2004, The LKB1 tumor suppressor negatively regulates mTOR signalling, Cancer Cell, 6, 91, 10.1016/j.ccr.2004.06.007 · DOI
  57. Brugarolas, 2004, Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex, Genes Dev., 18, 2893, 10.1101/gad.1256804 · DOI · Paper page
  58. Han, 2004, Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions, Cancer Res., 64, 812, 10.1158/0008-5472.CAN-03-3277 · DOI
  59. Gutmann, 2000, Expression of the tuberous sclerosis complex gene products, hamartin and tuberin, in central nervous system tissues, Acta Neuropathol. (Berl.), 99, 223, 10.1007/PL00007431 · DOI
  60. Murthy, 2001, Developmental expression of the tuberous sclerosis proteins tuberin and hamartin, Acta Neuropathol. (Berl.), 101, 202, 10.1007/s004010000269 · DOI · Paper page
  61. Kuzmiak, 2006, Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges, Trends Mol. Med., 12, 306, 10.1016/j.molmed.2006.05.005 · DOI
  62. de Vries, 2007, The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC), Eur. Child Adolesc. Psychiatry, 16, 16, 10.1007/s00787-006-0570-3 · DOI
  63. Jeganathan, 2002, Nonsense-mediated RNA decay in the TSC1 gene suggests a useful tool pre- and post-positional cloning, Hum. Genet., 111, 555, 10.1007/s00439-002-0821-4 · DOI
  64. Nellist, 2001, TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex, Hum. Mol. Genet., 10, 2889, 10.1093/hmg/10.25.2889 · DOI
  65. Mayer, 2004, Characterisation of a novel TSC2 missense mutation in the GAP related domain associated with minimal clinical manifestations of tuberous sclerosis, J. Med. Genet., 41, e64, 10.1136/jmg.2003.010835 · DOI
  66. Nellist, 2005, Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex, Eur. J. Hum. Genet., 13, 59, 10.1038/sj.ejhg.5201276 · DOI
  67. Jansen, 2006, Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation, Ann. Neurol., 60, 528, 10.1002/ana.21037 · DOI

Cited by

Sorted by citations

See all 84

Metadata

Authors
de Vries, P. J., & Howe, C. J.
Venue
Trends in Molecular Medicine
Publisher
Elsevier BV
Published
2007-08
Volume
13
Issue
8
Pages
319-326
ISSN
1471-4914
DOI
10.1016/j.molmed.2007.06.003
Cited by
84
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review